Ablation of Nonneoplastic Barrett's Mucosa Using Argon Plasma Coagulation with Concomitant Esomeprazole Therapy (APBANEX): A Prospective Multicenter Evaluation

Manner, Hendrik; May, Andrea; Miehlke, Stephan; Dertinger, Stephan; Wigginghaus, Bernd; Schimming, Wolfgang; Krämer, Walter; Niemann, Gabriele; Stolte, Manfred; Ell, Christian
August 2006
American Journal of Gastroenterology;Aug2006, Vol. 101 Issue 8, p1762
Academic Journal
BACKGROUND: Complete reversal of Barrett's epithelium (BE) achieved by treatment with argon plasma coagulation (APC) is variable. The aim of this prospective study was to evaluate the effectiveness of high-power APC in a multicenter trial. METHODS: In seven study centers, 60 patients (mean age 57, range 27–77) with nonneoplastic BE (length 1–8 cm) were recruited for treatment with high-power APC (90 W) in combination with esomeprazole 80 mg/day. Video endoscopy, chromoendoscopy, and four-quadrant biopsies (4QB) were carried out during baseline endoscopy and regular intervals. The effect of ablation was classified as complete remission (CR), partial remission, or minor response. RESULTS: Fifty-one of the 60 patients completed ablation therapy. Three patients were lost to follow-up (FU). After a mean of 2.6 APC sessions (range 1–5) and a mean FU of 14 months (range 12–32), CR was achieved in 37 of 48 patients (77%). Major complications occurred in five of 51 patients (9.8%). CONCLUSIONS: Complete ablation of BE can be achieved in a high percentage of patients even in a multicenter design using high-power APC. However, APC has a relevant morbidity. Therefore, ablation of nonneoplastic BE cannot be recommended generally because incidence of cancer in BE is low.


Related Articles

  • Studies on Formulation and Evaluation of Esomeprazole Buccal Patches. Kirankumar, Shah Harsh; Mahendrabhai, Maheshwari Mittal // Journal of Pharmacy Research;2012, Vol. 5 Issue 8, p4566 

    Esomeprazole is class of drug called proton pump inhibitors used in treatment of gastro esophagus reflux disease. Buccoadhesive buccal delivery systems for Esomeprazole in the form of unidirectional buccal patches were developed and characterized for improving bioavailability. The patches were...

  • Oral Melanoacanthoma: A Case Report, a Review of the Literature, and a New Treatment Option. Andrews, Brian T.; Trask, Douglas K. // Annals of Otology, Rhinology & Laryngology;Sep2005, Vol. 114 Issue 9, p677 

    Objectives: Oral melanoacanthoma is a rare condition that presents as a pigmented, painful lesion, most commonly on the buccal mucosa. Argon plasma coagulation is a new treatment option for benign oral lesions and is hypothesized to be efficacious for this rare mucosal disorder. Methods:...

  • Spectrophotometric Determination of Certain Benzimidazole Proton Pump Inhibitors. SYED, A. A.; SYEDA, AYESHA // Indian Journal of Pharmaceutical Sciences;2008, Vol. 70 Issue 4, p507 

    Spectrophotometric method for the determination of certain proton pump inhibitors belonging to the benzimidazole class of compounds has been developed. The method is based on the reaction of omeprazole, lansoprazole, pantoprazole, rabeprazole and esomeprazole with iron (III) and subsequent...

  • Long-term PPI therapy safe.  // Reactions Weekly;May2015, Vol. 1553 Issue 1, p7 

    The article focuses on a study which shows that long-term treatment with the proton pump inhibitors omeprazole and esomeprazole is not linked with any safety concern.

  • A Prospective Randomized Trial of Esomeprazole- versus Pantoprazole-Based Triple Therapy for Helicobacter pylori Eradication. Ping-I Hsu; Kwok-Hung Lai; Chiun-Ku Lin; Wen-Chi Chen; Hsien-Chung Yu; Jin-Shiung Cheng; Feng-Woei Tsay; Chung-Jen Wu; Ching-Chu Lo; Hui-Hwa Tseng; Yoshio Yamaoka; Jin-Liang Chen; Gin-Ho Lo // American Journal of Gastroenterology;Nov2005, Vol. 100 Issue 11, p2387 

    OBJECTIVE: This prospective, randomized, controlled, head-to-head study was conducted to compare the efficacies of esomeprazole- and pantoprazole-based triple therapies for Helicobacter pylori eradication. METHODS: From January 2002 to October 2003, 200 H. pylori-infected patients were randomly...

  • Esomeprazole therapy for gastric acid hypersecretion in children with cystinosis. Dohil, Ranjan; Fidler, Meredith; Barshop, Bruce; Newbury, Robert; Sellers, Zachary; Deutsch, Reena; Schneider, Jerry // Pediatric Nephrology;Dec2005, Vol. 20 Issue 12, p1786 

    Oral cysteamine therapy prevents natural disease progression in children with cystinosis, but it may cause severe gastrointestinal (GI) symptoms through gastric acid-hypersecretion. The purpose of this study was to assess the value of esomeprazole in controlling cysteamine-induced...

  • Esomeprazole.  // Reactions Weekly;Oct2013, Issue 1475, p18 

    The article presents a case study of a 76-year-old man who, while receiving esomeprazole, developed severe hypomagnesaemia. The patient had a history of high BP, diabetes mellitus, confusional episodes, atrial arrhythmia, dyslipidaemia and epileptic seizures. It is commented that recurrent...

  • Economic analysis of on-demand maintenance therapy with proton pump inhibitors in patients with non-erosive reflux disease. Hughes, Dyfrig A.; Bodger, Keith; Bytzer, Peter; de Herdt, Dirk; Dubois, Dominique // PharmacoEconomics;2005, Vol. 23 Issue 10, p1031 

    Aim: To evaluate the costs and effectiveness of on-demand maintenance therapy with oral esomeprazole, lansoprazole, omeprazole, pantoprazole or rabeprazole in patients with endoscopy-confirmed non-erosive reflux disease (NERD) in the UK.Methods: A probabilistic model...

  • The anti-secretory and anti-ulcer activities of esomeprazole in comparison with omeprazole in the stomach of rats and rabbits. Salim Bastaki; Irwin Chandranath; Jaipaul Singh // Molecular & Cellular Biochemistry;Feb2008, Vol. 309 Issue 1/2, p167 

    Abstract   Proton pump inhibitors (PPIs) are widely used to treat hyperacid secretion and stomach ulcers. The study investigated the anti-secretory and anti-ulcer effects of esomeprazole, the S-isomer of omeprazole on dimaprit, histamine and dibutyryl adenosine 3, 5 cyclic...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics